Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

pH4HIF Effect of pH on colloidal structures in human intestinal fluids and intestinal absorption of anticancer drugs

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 September 2023 to 31 August 2025
Status
Running
EU funding
€176k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108993

What the project is doing

In the project's own words, from its summary on CORDIS.

Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating thecorrect oral dose to achieve a therapeutic effect is an important challenge when developing drug products. Predicting intestinal drugabsorption needs to consider multiple influencing factors, including properties of the drug, the formulation, and the human intestinalfluids (HIF). One of the critical factors of HIF is pH, as it may influence intestinal drug absorption both directly and indirectly.

The directeffect of pH on a drugs ionisation state and, subsequently, intestinal absorption is widely known. However, the effect of pH on thesolubilisation and absorption of lipophilic drugs by changing the colloidal structures present in HIF, has not yet been systematicallyanalysed. Understanding this indirect pH effect is especially needed to improve dose predictions for drugs with a narrow therapeutic windowsuch as anticancer drugs, and address both inefficiency and potential side effects.

The proposed project therefore aims to understandand predict the pH effect on colloidal structures in HIF and how it affects the absorption potential of anticancer drugs in both fastedand fed state conditions. To achieve its goal, the project combines the expertise of the host group at KU Leuven in absorption profiling using in vitro and invivo methods with the applicants experience in predictive in silico modelling. This approach will provide unique insights into theindirect pH effect on drug absorption and contribute to the development of in silico predictive models to guide the early-stageformulation and dose optimisation of anticancer drugs.

As such, the project will have important value for pipelining new anticancerdrugs and will benefit the European Commission priorities for 2019-2024, such as the pharmaceutical strategy and Europes BeatingCancer Plan.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Sofia University St Kliment OhridskiSofiaBulgariaAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI